ClinicalTrials.gg
RecruitingNCT06320444Updated Mar 20, 2024

Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease

An observational study in Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Motor Neuron Disease Progressive Spinal Muscle Atrophy and Primary Lateral Sclerosis, sponsored by University of Dublin, Trinity College. Recruiting at 1 site in Ireland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by University of Dublin, Trinity College · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Amyotrophic Lateral Sclerosis with a site in Ireland — 5 open to participants now, 11 under way, 4 of them phase 3. Amyotrophic Lateral Sclerosis · Ireland.

Started
2023
with 1 other
Observational
6 of 32
3 open now
Primary completion
2024-12
later than 2 of 10 live
Registered
26th of 32
by date
Lead sponsor
4 of 32
University of Dublin, Trinity College

Among the 32 studies in Amyotrophic Lateral Sclerosis with a site in Ireland, this one is one of 2 that started in 2023, is one of 6 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 26th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

5 of the 32 studies in Amyotrophic Lateral Sclerosis with a site in Ireland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Ireland have not opened yet or have stopped. Only those recruiting at a site in Ireland →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Amyotrophic Lateral Sclerosis with a site in Ireland, or all of them as a file.
02

Study summary

Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS). This variability requires biomarkers that accurately classify and reliably track clinical subtypes as the disease progresses. Degeneration occurs in the brain and spinal cord, however, non-invasive diagnosis of spinal cord function remains highly challenging due to its unique alignment in spine. Disruption of complex spinal and cortical circuits that transmit and process neural signals for position sense and movement has not been adequately captured in the neurophysiological profiling of ALS patients. The overarching aim of this study is to reveal and quantify the extent of change in the sensorimotor integration and its potential contribution to network disruption in ALS.

Read the detailed description

Background:

Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS). This variability requires biomarkers that accurately classify and reliably track clinical subtypes as the disease progresses. Degeneration occurs in the brain and spinal cord, however, non-invasive diagnosis of spinal cord function remains highly challenging due its unique alignment in the spine. Disruption of complex spinal and cortical circuits that transmit and process neural signals for position sense and movement has not been adequately captured in the neurophysiological profiling of ALS patients.

Aim:

To develop, test, and employ non-invasive techniques to explore (dys)function between motor, sensory brain, and spinal networks in ALS. The project will address if the electrical activity of the cortical-spinal network by the of use peripheral stimulation (vibration, electrical nerve stimulation) to probe and reveal the normal or abnormal communication between brain and spinal networks. It is expected to reveal novel neurophysiological signatures in ALS patients compared to healthy controls.

Study Design \& Data Analysis:

Surface electrodes will be mounted over the targeted regions in conjunction with High-Density EEG and High-density Electromyography (EMG). A physical and mathematical model of the underlying sources of electric activity (source localization) will be carried out at rest, during task, and with non-invasive peripheral nerve stimulation (PNS) and TMS. A separate paradigm will augment sensorimotor communication between the primary motor cortex (M1) and the somatosensory cortex (S1). Mild vibration (5N/\< 500 grams) will be applied to the wrist and/or bicep tendon transcutaneously. Vibration in conjunction with non-invasive peripheral nerve stimulation will induce transient changes (30 seconds maximum) in the intrinsic excitability of motor neurons in the spinal cord. Surface EMG will capture altered MN activity at the spinal level and the anticipated augmented communication in cortical networks (S1-M1) will be captured with EEG through connectivity analysis. Non-invasive transcranial magnetic stimulation in conjunction with vibration/nerve stimulation will be recorded to explore upper motor neurone influences on the altered intrinsic excitability of spinal motor neurons.

Data collection:

EXG-EEG-EMG and TMS/Peripheral Stimulation recordings will be conducted using a BioSemi® ActiveTwo system with 128 active sintered Ag-AgCl electrodes and headcaps (BioSemi B.V., Amsterdam, The Netherlands). The TMS system is a Brainbox DuoMAG (Brainbox Ltd., Cardif, Wales, UK) which can be used with a Digitimer peripheral stimulator.

03

Conditions studied

  • Motor Neuron Disease, Amyotrophic Lateral Sclerosis
  • Motor Neuron Disease Progressive Spinal Muscle Atrophy
  • Primary Lateral Sclerosis
  • Multiple Sclerosis
  • Postpoliomyelitis Syndrome

Keywords

  • Electroencephalography (EEG)
  • Peripheral Nerve Stimulation
  • Vibration-Induced Stimulation
  • Neurodegeneration
  • Electrophysiology
  • Biomarkers
  • Neuromuscular Physiology
  • Spinal Connectivity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy controls and patients diagnosed with ALS, MS, PLS, PMA, and SMA.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Healthy Volunteers:

  • age and gender matched to patient groups
  • intact physical ability to take part in the experiment.

Patients:

  • Diagnosis of ALS, PLS, PMA, SMA, Polio or MS
  • capable of providing .

Exclusion criteria

Exclusion Criteria:

-

Healthy Controls:

  • History of neuromuscular
  • neurological or active psychiatric disease disease
  • history of reaction or allergy to recording environments, equipment and the recording gels.

Patients:

  • presence of active psychiatric disease
  • any medical condition associated with severe neuropathy (e.g. poorly controlled diabetes).
  • History of reaction or allergy to recording environments, equipment and the recording gels.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Controls

    Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis

    Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)

  • Amyotrophic lateral sclerosis Patients

    Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)

  • Multiple Sclerosis patients

    Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)

  • Postpoliomyelitis syndrome patients

    Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)

  • Muscular Atrophy patients

    Procedure: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)

Interventions

  • Procedure232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)

    Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task. Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation. These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory)

    Also known as: Peripheral Nerve Stimulation, Vibration Induced Stimulation

06

What researchers measure

Primary outcomes

  1. Biomarker of sensorimotor integration

    A viable biomarker of sensorimotor integration for reliable and early distinction between healthy people and Motor Neuron Disease patient sub-phenotypes. This will be achieved by comparing connectivity measures between EEG, Non-cortical CNS, and EMG electrophysiological signals. The integration will also be seen in spectral analysis measures.

    Time frame: Baseline to 2-years after baseline

  2. Determination of the feasibility of sensorimotor signatures as reliable biomarkers of ALS

    The sensorimotor integration and signature biomarkers achieved during outcome 1 will be correlated with the clinical scores and will be statistically tested for reliability and robustness. The effect sizes of these statistical and correlation matrices will be used to evaluate the feasibility of the signatures as reliable biomarkers for motor neuron conditions like ALS.

    Time frame: Baseline

  3. Non-invasive recording of the SC functional neuro-electric activity

    Understanding the role of spinal cord (SC) in neuromuscular physiology (in both impaired and healthy individuals) and will also assist in discovering biomarkers in Brain-SC Peripheral connections. This is a perspective outcome that will be future based upon the inferences gained by the first two outcomes.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Academic Unit of Neurology, Trinity College Dublin, The University of Dublin
    Dublin, Leinster Dublin 2, Ireland
    Recruiting
    • Orla Hardiman,, BSc MB BCh BAO MD FRCPI FAAN · Contacthardimao@tcd.ie · +353 1 896 4497
    • Prabhav Mehra, BE MSc · Contactmehrap@tcd.ie · +3530894781347‬
08

References and documents

Individual participant data

Plan to share: Yes — Raw data from this study may be made available in anonymized form upon request from qualified investigators subject to the approval by the Data Protection Office (DPO) and Office of Corporate Partnership and Knowledge Exchanges (OCPKE) in Trinity College Dublin, the University of Dublin.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Due to ethical constraints and the time required for data quality checks, data will only be made available in fully anonymised format following the publication of results.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2024, 18 months after the start.

Of 129 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 18 months is below that.

Counting every sponsor, half of 138 studies reached it within 64 months; a quarter within 29 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2022
First posted
Mar 20, 2024
StartActual
Jun 15, 2023
Primary completionEst.
Dec 15, 2024
CompletionEst.
Jul 15, 2025
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06320444
Lead sponsor
University of Dublin, Trinity College
Collaborators
Motor Neurone Disease Association, UK, Irish Research Council, IE, Health Research Board, IE, Research Motor Neurone, IE, Thierry Latran Foundation, FR, ALS Association, USA
Responsible party
Orla Hardiman (Professor of Neurology, University of Dublin, Trinity College) — Principal investigator
First posted
Mar 20, 2024
Start date
Jun 15, 2023
Primary completion
Dec 15, 2024 (estimated)
Completion
Jul 15, 2025 (estimated)
Last update
Mar 20, 2024

Study contacts

Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN
Contact
hardimao@tcd.ie
+353 1 896 4497
Prabhav Mehra, B.E. MSc.
Contact
mehrap@tcd.ie
+353 0894781347
Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN
principal investigator · Academic Unit of Neurology, Trinity College Dublin, The University of Dublin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion